Form 4: Mineralys Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Eric Warren, Chief Commercial Officer of Mineralys Therapeutics, Inc., sold 7,438 shares of common stock on July 21, 2026 for $26.87 per share.
Summary
- Option exercise/conversion: acquired 7,438 Common Stock at $13.24 ($98,479) on July 21, 2026; holds 45,838 after (Direct).
- Open-market sale: disposed of 7,438 Common Stock at $26.87 ($199,885) on July 21, 2026; holds 38,400 after (Direct).
- Option exercise/conversion: disposed of 7,438 Stock Option on July 21, 2026; holds 245,438 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $199,885 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Eric Warren — Officer (Chief Commercial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-21 | Option exercise/conversion | Common Stock | 7,438 | $13 | $98.5K | 45,838 |
| 2026-07-21 | Open-market sale | Common Stock | 7,438 | $27 | $199.9K | 38,400 |
| 2026-07-21 | Option exercise/conversion | Stock Option | 7,438 | — | — | 245,438 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-21 | Option exercise/conversion (7,438 shares) |
| 2026-07-21 | Open-market sale (7,438 shares) |
| 2026-07-21 | Option exercise/conversion (7,438 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., bearish, Eric Warren
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.